The Changes of Serum PCSK9 and CCL20 Levels in Patients with HER-2 Positive Breast Cancer before and after Chemotherapy with Buxue Yangxin Anticancer Decoction Assisted Docetaxel+Carboplatin were Retrospectively Analyzed
The Changes of Serum PCSK9 and CCL20 Levels in Patients with HER-2 Positive Breast Cancer before and after Chemotherapy with Buxue Yangxin Anticancer Decoction Assisted Docetaxel+Carboplatin were Retrospectively Analyzed
Objective:To analyze the changes in serum proprotein convertase subtilisin/kexin type 9 (PCSK9) and chemokine ligand 20 (CCL20) levels in patients with human epidermal growth factor receptor-2 (HER-2) positive breast cancer before and after treatment with Buxue Yangxin Kangai Decoction assisted with docetaxel+carboplatin chemotherapy. Methods:The data of 82 patients with HER-2 positive breast cancer from January 2021 to January 2023 were retrospectively analyzed and divided into a control group and an observation group according to different treatment regimens,with 41 cases in each group. The control group was treated with docetaxel+carboplatin chemotherapy,and the observation group was treated with Buxue Yangxin Kangai Decoction assisted with docetaxel+carboplatin chemo-therapy. One cycle was 21 days,and both groups were treated for 6 cycles. The clinical efficacy,TCM syndrome score,HER-2 expression,PCSK9,CCL20 and adverse reactions were compared between the two groups. Results:The clini-cal efficacy of the observation group (58.54％) was higher than that of the control group (36.59％);compared with the control group,the main symptoms,secondary symptoms and total score of TCM syndrome in the observation group after treatment were lower;after treatment,the HER-2 negative conversion rate in the observation group was higher than that in the control group,and the HER-2 strong positive expression rate was lower than that in the control group;compared with before treatment,PCSK9 and CCL20 in both groups decreased,and the observation group was more significant,and the differences were statistically significant. There was no significant difference in the incidence of adverse reac-tions such as nausea and vomiting,alopecia,cardiotoxicity,and bone marrow suppression between the two groups. Con-clusion:The Buxue Yangxin Kangai Decoction assisted with docetaxel+carboplatin chemotherapy regimen can down-regulate the expression of PCSK9 and CCL20 in the treatment of HER-2 positive breast cancer,effectively control the disease,promote HER-2 negative conversion,and has significant efficacy and high safety.
维普
万方数据